A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients With Relapsed or Refractory AML or CMML

MKIA-088-001

The purpose of this study is to explore safety, tolerability, including the maximum tolerated dose and the recommended Phase II dose (RP2D), and antitumor activity of NMS-03592088 in adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML).

2019-04-03

2025-12-28

2026-02-28

Recruiting

Early phase I

200

Inclusion Criteria: * Patients with relapsed/refractory disease who have failed standard therapy or are unsuitable for standard treatment, with one the following confirmed diagnosis: AML as defined by the European LeukemiaNet (ELN) * Patients with confirmed diagnosis of AML as defined by the 2022 ELN recommendations * Patients must have failed standard of care. * Adult (age ≥ 18 years) patients * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * The interval from prior antitumor treatment to time of NMS-03592088 administration should be at least 2 weeks for any agents other than hydroxyurea. * All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to NCI CTCAE version 5.0 Grade ≤1 * Adequate hepatic and renal function * Patients must use highly effective contraception. * Signed and dated IEC or IRB-approved informed consent form. Exclusion Criteria: * Current enrollment in another interventional clinical study * Diagnosis of acute promyelocytic leukemia or Breakpoint cluster region-Abelson (BCR-ABL)-positive leukaemia * Currently active second malignancy, except for adequately treated basal or squamous cell skin cancer and/or cone biopsied in situ carcinoma of the cervix uteri and/or superficial bladder cancer. * Patients with known leukemia involvement of central nervous system (CNS) * Hematopoietic stem cell transplantation (HSCT) within 3 months of treatment start and/or persistent non-hematologic toxicities of Grade ≥2 related to the transplant * Active acute or chronic graft versus host disease (GVHD) requiring immunosuppressive treatment * Patients with QTcF interval ≥ 480 milliseconds or with risk factors for torsade de pointes * Pregnancy. * Breast-feeding or planning to breast feed during the study or within 3 months after study treatment. * Any of the following in the previous 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis * Known active, life threatening or clinically significant uncontrolled systemic infection. * Known active gastrointestinal disease * Known active gastrointestinal ulcer * Other severe or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation. * Known diagnosis of myasthenia gravis US only: * Signs or symptoms of myasthenia gravis or stroke during screening * Patients with myasthenia gravis specific autoantibodies or any known history of myasthenia gravis (MG) autoantibodies at screening window * Concomitant medications with the potential to cause de novo myasthenia gravis, worsening of myasthenia gravis or cause myasthenia gravis-like symptoms * Uncontrolled hypertension, atrial fibrillation or flutter, ventricular arrhythmia or receiving treatment for cardiac rhythm disorder or diabetes that is not adequately controlled Other protocol specific inclusion/exclusion criteria may apply

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SEQUENTIAL', 'interventionModelDescription': 'This is an open-label Phase I/II, first-in-human (FIH), non-randomized, multi-center study conducted in two parts: a Phase I including patients with AML and CMML and a Phase II exploratory study comprising two parallel cohorts of AML FLT3 mutated patients.\n\nThe Phase II portion of the study is currently being conducted in EU only.', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 200, 'type': 'ESTIMATED'}}

2024-02-21